<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334110</url>
  </required_header>
  <id_info>
    <org_study_id>Z151100004015177</org_study_id>
    <nct_id>NCT03334110</nct_id>
  </id_info>
  <brief_title>A Clinical Randomized Controlled Trial of the New Method of Selective Coronary Vein Bypass Graft (SCVBG)</brief_title>
  <official_title>Clinical Randomized Controlled Trial of the New Method of Selective Coronary Venous Bypass Graft on Improving Curative Effects in Patients With Diffuse Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apply a new operation method of Left Internal Mammary Artery (LIMA)-Greater Saphenous Vein
      (GSV)-SCVBG to the treatment of patients with diffuse coronary artery disease,through
      clinical randomized controlled study,compared with patients of bilateral internal mammary
      artery (BIMA)-SCVBG and evaluate both of therapeutic effects and prognosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The patency rate of bridge vessels and selective coronary vein</measure>
    <time_frame>1-3 years</time_frame>
    <description>We will assess the patency rate during a follow-up of 1 year, and continue to follow up to 3 years after the end of the project</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Main adverse cardiovascular and cerebrovascular events</measure>
    <time_frame>1-3 years</time_frame>
    <description>We will follow up the main adverse cardiovascular and cerebrovascular events ( death, myocardial infarction, stroke and repeated revascularization) 7 days, 1 month, 3 months, 6 months and 1 year after the operation and continue to 3 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound complications</measure>
    <time_frame>1-3 years</time_frame>
    <description>We will follow up the wound complications (sternum and mediastinal infection, incision infection, fat liquefaction) 7 days, 1 month, 3 months, 6 months and 1 year after the operation and continue to 3 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Coronary Atherosclerotic Heart Disease</condition>
  <arm_group>
    <arm_group_label>LIMA-GSV-SCVBG Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group: The intervention：we apply a new operation on the patients with diffuse coronary artery disease(DCAD), we choose LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIMA-SCVBG Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The other group：The intervention: We choose bilateral internal mammary artery composited LIMA-Right Mammary Internal Artery（RIMA） y graft， and anastomose the RIMA with selective coronary vein.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>A method of operation: LIMA-GSV-SCVBG</intervention_name>
    <description>On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein</description>
    <arm_group_label>LIMA-GSV-SCVBG Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BIMA-SCVBG</intervention_name>
    <description>On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.</description>
    <arm_group_label>BIMA-SCVBG Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with right coronary artery diffuse lesions:Right coronary artery
             lumen≤1mm，Lesion lengths ≥20mm or multiple segment lesions.

          -  Patients of coronary artery bypass grafting (CABG) that can't be treated through
             endarterectomy.

          -  Patients ≤ 70 years old.

          -  All enrolled patients must being signed the informed consent.

        Exclusion Criteria:

          -  Severe heart failure(ejection fraction under 35%) or non coronary atherosclerotic
             heart disease patients such as combined with severe valvular heart disease.

          -  Patients with acute myocardial infarction.

          -  Assistant examinations indicate that the bridge vessels can't be used；The left
             subclavian artery stenosis and/or LIMA lesions；RIMA lesions；varicosis of both great
             saphenous vein.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing An Zhen Hospital , Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yang yu, doctor</last_name>
      <phone>13911534101</phone>
      <email>15915901281629@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Yang Yu</investigator_full_name>
    <investigator_title>Professor；Chief Physician；</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

